Scottie Scheffler earned another comparison with Tiger Woods on Monday, joining him as the only players to win PGA Tour player of the year at least four times in a row.
Scheffler made an easy case to pick up another Jack Nicklaus Award. His tour-leading six victories were twice as many as anyone else and included two majors, the PGA Championship and the British Open, to leave him on the cusp of a career Grand Slam.
Click to Gallery
Scottie Scheffler, of the United States, hits from the bunker on the 10th hole during the final round of the Hero World Challenge PGA Tour at the Albany Golf Club, in New Providence, Bahamas, Sunday, Dec. 7, 2025. (AP Photo/Fernando Llano)
Scottie Scheffler, of the United States, reacts after his shot on 18th green during the third round of the Hero World Challenge PGA Tour at Albany Golf Club in New Providence, Bahamas, Saturday, Dec. 6, 2025. (AP Photo/Fernando Llano)
Scottie Scheffler, of the United States, reacts to making a birdie on the fourth hole during the third round of the Hero World Challenge PGA Tour at the Albany Golf Club, in New Providence, Bahamas, Saturday, Dec. 6, 2025. (AP Photo/Fernando Llano)
FILE - Scottie Scheffler of the United States holds the Claret Jug trophy as he poses for photographers after winning the British Open golf championship at the Royal Portrush Golf Club, Northern Ireland, July 20, 2025. (AP Photo/Peter Morrison, File)
He became the first player since Woods in 2000 to lead the PGA Tour with the lowest scoring average in each of the four rounds and had 15 consecutive tournaments in the top 10 to end his remarkable season.
“I think overall the thing that I’m most proud of when I look at the last couple years is just consistency,” Scheffler said on a conference call. “It’s not very easy to just show up and finish in the top 10 each week. I think that’s something that’s very difficult to do and something I’m very proud of, bringing the intensity that I need to in these tournaments and being prepared as I need to in order to perform well week in and week out.”
Scheffler was on the ballot with Rory McIlroy, Tommy Fleetwood and Ben Griffin. The award is a vote of the players, though the PGA Tour did not release what percentage of the votes Scheffler received or how many players voted.
Woods is an 11-time winner of the award and won five straight times from 1999 through 2003.
McIlroy had a big year in his own right, nothing grander than his playoff victory in the Masters for the final leg of the career Grand Slam and a green jacket he had been pursuing for 15 years. He also added titles at Pebble Beach and The Players Championship.
Scheffler, however, has been putting on a master class of consistency since breaking through with his first PGA Tour title in 2022. Along with 19 victories in his last 80 events on the PGA Tour — that doesn't include his Olympic gold medal last year in Paris — Scheffler has finished among the top three in just over 46% of his PGA Tour starts.
This season alone, Scheffler led the PGA Tour in 17 statistical categories, ranging from his accuracy from tee-to-green, how often he followed a bogey with a birdie or better (36%) and official earnings, which this year topped $27 million.
And he effectively gave McIlroy and everyone else a head start. Scheffler sliced his right hand during Christmas last year while using a wine glass to cut ravioli. He missed nearly two months and didn't really find his groove until a week before the Masters when he was runner-up in Houston.
That began an astonishing stretch in which Scheffler didn't finish worse than a tie for eighth the rest of the year. He played his final six PGA Tour events without a round over par, and he had a stretch of 21 consecutive rounds in the 60s.
He also won his hometown CJ Cup Byron Nelson in the Dallas area by matching the PGA Tour record for 72 holes at 253, an eight-shot victory.
“Yeah, I definitely didn’t start off the way I intended to start off,” Scheffler said. “I missed the first couple weeks of the season but did a good job of bouncing back from that. I started to play some pretty good golf in May.”
Neither of his two major titles was particularly close. He won the PGA Championship at Quail Hollow by five shots and the British Open at Royal Portrush by four shots. In all four of his majors — he also won the Masters in 2022 and 2024 — he has had at least a four-shot lead going to the final hole. Missing is a tense finish to a major.
“I’m not really picky. If I’m holding the trophy at the end, it doesn’t really matter,” Scheffler said with a laugh.
Aldrich Potgieter was voted PGA Tour rookie of the year. He was among five rookies who won this year, but the South African was the only player to win a tournament that offered full FedEx Cup points and qualify for the postseason.
AP golf: https://apnews.com/hub/golf
Scottie Scheffler, of the United States, hits from the bunker on the 10th hole during the final round of the Hero World Challenge PGA Tour at the Albany Golf Club, in New Providence, Bahamas, Sunday, Dec. 7, 2025. (AP Photo/Fernando Llano)
Scottie Scheffler, of the United States, reacts after his shot on 18th green during the third round of the Hero World Challenge PGA Tour at Albany Golf Club in New Providence, Bahamas, Saturday, Dec. 6, 2025. (AP Photo/Fernando Llano)
Scottie Scheffler, of the United States, reacts to making a birdie on the fourth hole during the third round of the Hero World Challenge PGA Tour at the Albany Golf Club, in New Providence, Bahamas, Saturday, Dec. 6, 2025. (AP Photo/Fernando Llano)
FILE - Scottie Scheffler of the United States holds the Claret Jug trophy as he poses for photographers after winning the British Open golf championship at the Royal Portrush Golf Club, Northern Ireland, July 20, 2025. (AP Photo/Peter Morrison, File)
BOSTON--(BUSINESS WIRE)--Dec 18, 2025--
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217152848/en/
Robert Lyne commented: “I’m honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I’ve seen first-hand the strength of our programs, the talent of our team, and the power of our differentiated model. I’m keen to build on this foundation, working closely with the Board to drive the next phase of execution as we advance transformative therapies for patients and deliver long-term value for our shareholders.
“Our immediate focus is on securing the funding needed to advance our newest Founded Entity, Celea Therapeutics, following the successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration. This process is progressing, and we expect to close within the first half of 2026, after which PureTech’s operational run rate will reduce significantly. In parallel, we are also actively pursuing financing in 2026 for Gallop Oncology, as the strong initial topline data continue to mature, and the program advances to the next stage of development.
“Going forward, we intend to operate with a streamlined structure and significantly reduced overhead. This will be combined with a disciplined investment posture, pursuing focused innovation initiatives that can be advanced to key inflection points with relatively modest spend to improve our return on capital. Once Celea is fully financed, we expect to evaluate the most effective means of delivering value to shareholders, including potential capital returns, as part of an integrated strategy that continues targeted and impactful innovation. In the meantime, our priority is preserving capital, maintaining flexibility, and positioning PureTech for value creation.”
Sharon Barber-Lui, Interim Chair of PureTech’s Board of Directors, said: “We are pleased to appoint Rob as PureTech’s CEO. As Interim CEO, Rob has demonstrated strong leadership, strategic clarity, and a deep understanding of the business and key stakeholders. Rob’s appointment positions the Company to execute against a clear plan to sharpen strategic and operational focus and optimize shareholder returns. The Board supports Rob’s disciplined approach to maintaining a lean operating model whilst concentrating on capital-efficient innovation to maximize shareholder value. The Board is confident that Rob is the right person to lead PureTech forward.”
Mr. Lyne has served as Interim CEO since July 2025 and joined PureTech in January 2024 as Chief Portfolio Officer. During his time as Interim CEO, Mr. Lyne has provided strong leadership for the business, overseeing progress across PureTech’s programs and advancing strategic and operational priorities. He is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. Mr. Lyne brings more than a decade of experience in senior leadership roles at London-listed life science companies, with a strong track record in governance and executive team leadership. He has been involved in over 80 venture capital financings across Europe and North America as well as multiple portfolio exits and initial public offerings.
Mr. Lyne was previously a director of Arix Bioscience plc within the past five years. There are no other details to be disclosed in respect of Mr. Lyne’s appointment pursuant to LR 9.6.13R.
About PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED
Robert Lyne, Chief Executive Officer of PureTech
